If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Rituximab in Progressive IgA Nephropathy

March 24, 2011

More Lupus Nephritis Clinical Trials

Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis
Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis (hUC-MSC-SLE)
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
ATLAS - Anti-Tweak in Lupus Nephritis Patients
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients

More in Lupus Nephritis Clinical Trials:

Long-Term Study of Multi-target Therapy as Continuous Induction and Maintenance Treatment for Lupus Nephritis

Rituximab in Progressive IgA Nephropathy

Sponsor and Collaborators
Mayo Clinic
Georgia Health Sciences University
Ohio State University
Stanford University
University of North Carolina, Chapel Hill
Vanderbilt University
Columbia University

Contact
Fernando C Fervenza, M.D.
507-266-7961
fervenza.fernando@mayo.edu

Shirley Jennison
507-255-0231
jennison.shirley@mayo.edu

Principal Investigator
Fernando C. Fervenza, M.D., Mayo Clinic

ClinicalTrials.gov Identifier
NCT00498368